Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for crohn's perineal fistulas

American Journal of Gastroenterology

Volumn 104, Issue 12, 2009, Pages 2973-2986

  Ng, Siew C ^a   Plamondon, Sophie ^a   Gupta, Arun ^a   Burling, David ^a   Swatton, Anna ^a   Vaizey, Carolynne J ^a   Kamm, Michael A ^a,b  

^a ST MARK S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CROHN FISTULA; DISEASE ACTIVITY; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALING; HUMAN; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; INTERVENTION STUDY; INTESTINE FISTULA; MALE; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERIANAL CROHN DISEASE ACTIVITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SURGICAL APPROACH; SURGICAL TECHNIQUE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERVENTION STUDIES; INTESTINAL FISTULA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PERINEUM; PROSPECTIVE STUDIES; QUESTIONNAIRES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 72949099874     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.509     Document Type: Article

References (46)

1. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn's disease. Ann Intern Med 2001;135:906-918
2. Lapidus A, Bernell O, Hellers G et al. Clinical course of colorectal Crohn's disease:35-year follow-up study of 507 patients. Gastroenterol 1998;114:1151-1160
3. Bell SJ, Halligan S, Windsor ACJ et al. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003;17:387-393
4. Brandt LJ, Bernstein LH, Boley SJ et al. Metronidazole therapy for perianal Crohn's disease: a follow-up study. Gastroenterol 1982;83:383-387
5. Bernstein LH, Frank MS, Brandt LJ et al. Healing of perianal Crohn's disease with metronidazole. Gastroenterology 1980;79:357-365
6. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984;79:533-540
7. Thia KT, Mahadaven U, Feagen BG et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009;15:17-24.
8. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-142
9. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998;93:442-448
10. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol 1993;88:646-649
11. Sandborn WJ, Present DH, Isaacs KL et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterol 2003;125:380-388
12. Gonzalez-Lama Y, Abreu L, Vera MI et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm Bowel Dis 2005;11:8-15.
13. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405 (Pubitemid 29205403)
14. Sands BE, Anderson FH, Berstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Eng J Med 2004;350:876-885
15. Lichtenstein GR, Yan S, Bala M et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulising Crohn's disease. Gastroenterol 2005;128:862-869
16. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM Trial. Gastroenterol 2007;132:52-65.
17. Kamm MA, Colombel JF, Sandborn WJ et al. Adalimumab maintains clinical remission and response, induces and maintains healing of draining fistulas in patients with active Crohn's Disease. Gut 2007;56 (Suppl II): A21.
18. Colombel J, Kamm MA, Schwartz DA et al. Sustainable efficacy of adalimumab on fistula healing in patients with moderate to severe Crohn's disease treated with adalimumab for 3 years. Gut 2008;57 (Suppl 1):307.
19. Ehrenpreis ED, Kane SV, Cohen LB et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterol 1999;117:1271-1277
20. Vasiliauskas EA, Kam LY, Abreu-Martin MT et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterol 1999;117:1278-1287
21. Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulising Crohn's disease resistant to standard therapy. Aliment, Pharmacol Ther 2007;25:557-567
22. Choen S, Burnett S, Bartram CI et al. Comparison between anal endosonography and digital examination in evaluation of anal fistulae. Br J Surg 1991;78:445-447
23. Chapple KS, Spencer JA, Windsor AC et al. Prognostic value of magnetic resonance imaging in the management of fistula-in-ano. Dis Colon Rectum 2000;43:511-516
24. Makowiec F, Laniado M, Jehle E et al. Magnetic resonance imaging in perianal Crohn's disease. Inflamm Bowel Dis 1995;1:256-265
25. Schwartz DA, Wiersema MJ, Dudiak KM et al. A comparison of endoscopic ultrasound, magnetic resonance imaging and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterol 2001;121:1064-1072
26. Van Assche G, Vanbeckevoort D, Bielen D et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003;98:332-339
27. Halligan S. Imaging fistula in ano. Clin Radiol 1998;53:85-95.
28. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976;63:1-12.
29. Vermeire S, Van Assche G, Rutgeerts P. Perianal Crohn's disease: classification and clinical evaluation. Dig Liv Dis 2007;39:959-962
30. Colombel JF, Kamm MA, Schwartz D et al. Sustained fistula healing and response with adalimumab for up to 2 years in patients with fistulising Crohn's disease:12 months of open-label maintenance with adalimumab following the CHARM trial. Gut 2008;57:089.
31. Bell SJ, Williams AB, Wiesel P et al. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 2003;17:1145-1151
32. Sands BE, Blank MA, Patel K et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-920
33. Colombel JF, Kamm MA, Schwartz D et al. Sustainability of adalimumab in fistula healing and response:2-year data from CHARM and 12-month open-label extension follow-up study. Am J Gastroenterol 2007;102: S497 [1034].
34. Colombel JF, Schwartz D, Sandborn WJ et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009;58:940-88 e-pub ahead of print.
35. Colombel JF, Loft us EV, Feagan BG et al. Impact of adalimumab (Humira) on patient-reported outcomes among patients with fistulising Crohn's disease. Am J Gastroenterol 2007;102: S457 [921].
36. Gomollon F, Hinojosa J, Nos P et al. Long term results of adalimumab treatment in subjects with moderately to severely active fistulizing Crohn's disease who have failed response or showed intolerance to infliximab. Gut 2007;56 (Suppl III): A152.
37. Lichtiger S, Binion D, Wolf DC et al. Fistula healing with adlimumab treatment in patients with Crohn's disease and previous exposure to infliximab. Gut 2008;57 (Suppl I): OP308.
38. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterol 2008;134:1861-1868
39. Lichtenstein GR, Diamond RH, Wagner CL et al. Benefits and risks of immunomodulators and maintenance infliximab for IBD: subgroup analyses across four randomized trials. Aliment Pharmacol Therapeutics 2009;30:210-226
40. Sandborn W, Rutgeerts P, Reinisch W et al. One year data from the SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease na ï ve to immunomodulators and biologic therapy. Gastroenterol 2009;136 (Suppl 1):751f.
41. Rasul I, Wilson SR, Macrae H et al. Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease. Am J Gastroenterol 2003;99:82-88
42. Karmiris K, Vanbeckevoort D, Bielen D et al. Baseline Magnetic resonance imaging predicts surgery in perianal Crohn's disease patients treated with infliximab: results from a long-term follow-up study. Gut 2008;57 (Suppl 1): OP213.
43. Calvo MI, Vera MI, De la Revilla J et al. Complex Perianal Crohn's disease: influence of the long-term maintenance treatment with infliximab on the fistulae tracks assessed through magnetic resonance imaging. J Crohn's Colitis 2008;2: P102.
44. Kugathasan S, Werlin SL, Martinez A et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-3194
45. Lionetti P, Bronzini F, Salvestrini C et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003;18:425-431
46. Spradlin NM, Wise PE, Herline AJ et al. A randomized prospective trial of endoscopic ultrasound to guide combination medical and surgical treatment for Crohn's perianal fistulas. Am J Gastroenterol 2008;103:2527-2535